Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode.

[1]  S. Cory,et al.  The BCL-2 arbiters of apoptosis and their growing role as cancer targets. , 2018 .

[2]  J. Montero,et al.  Why do BCL-2 inhibitors work and where should we use them in the clinic? , 2017, Cell Death and Differentiation.

[3]  Jana Sopkova-de Oliveira Santos,et al.  Toward Understanding Mcl-1 Promiscuous and Specific Binding Mode , 2017, J. Chem. Inf. Model..

[4]  J. Visvader,et al.  Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer , 2017, Science Translational Medicine.

[5]  P. Hughes.  Abstract DDT01-01: The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma , 2017 .

[6]  A. Coxon,et al.  Abstract 2027: Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models , 2017 .

[7]  Shuang Liu,et al.  Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells , 2017, Signal Transduction and Targeted Therapy.

[8]  A. Ashkenazi,et al.  From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors , 2017, Nature Reviews Drug Discovery.

[9]  S. Corvaisier,et al.  Comparison of 2 strategies to enhance pyridoclax solubility: Nanoemulsion delivery system versus salt synthesis , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  L. Poulain,et al.  The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737 , 2016, Molecular Cancer Therapeutics.

[11]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[12]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[13]  D. Huryn,et al.  Structure Property Relationships of Carboxylic Acid Isosteres , 2016, Journal of medicinal chemistry.

[14]  E. Olejniczak,et al.  Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. , 2016, Journal of medicinal chemistry.

[15]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[16]  L. Howell,et al.  Small‐Molecule and Peptide Inhibitors of the Pro‐Survival Protein Mcl‐1 , 2015, ChemMedChem.

[17]  John Calvin Reed,et al.  Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. , 2015, Blood.

[18]  T. Chambers,et al.  BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. , 2015, Cancer research.

[19]  S. Lheureux,et al.  Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An ex vivo experiment in human serous ovarian carcinoma , 2015, International journal of cancer.

[20]  Scott A. Erickson,et al.  Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. , 2015, Journal of medicinal chemistry.

[21]  S. Rault,et al.  First evidence that oligopyridines, α-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies. , 2015, Journal of medicinal chemistry.

[22]  L. Poulain,et al.  Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation , 2015, Apoptosis.

[23]  C. Tse,et al.  Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) , 2015, Cell Death and Disease.

[24]  S. Rault,et al.  Focus on Microwaves Assisted Halogen-halogen Exchange Reaction Conditions on 2-Halopyridines , 2014 .

[25]  S. Lheureux,et al.  PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. , 2014, Cancer letters.

[26]  Chang Park,et al.  Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein. , 2014, Bioorganic & medicinal chemistry letters.

[27]  Dmitriy Minond,et al.  Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker. , 2013, Bioorganic & medicinal chemistry.

[28]  Jana Sopkova-de Oliveira Santos,et al.  Conformation Control of Abiotic α-Helical Foldamers , 2013, J. Chem. Inf. Model..

[29]  S. Rault,et al.  Targeting the BH3 domain of Bcl-2 family proteins. A brief history from natural products to foldamers as promising cancer therapeutic avenues. , 2013, Current medicinal chemistry.

[30]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[31]  Alexander D. MacKerell,et al.  Extension of the CHARMM general force field to sulfonyl‐containing compounds and its utility in biomolecular simulations , 2012, J. Comput. Chem..

[32]  J. Opferman,et al.  A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. , 2012, Chemistry & biology.

[33]  Hong-Gang Wang,et al.  Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. , 2012, Journal of the American Chemical Society.

[34]  Alexander D. MacKerell,et al.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.

[35]  S. Rault,et al.  Using halo (het) arylboronic species to achieve synthesis of foldamers as protein–protein interaction disruptors , 2012 .

[36]  R. Rossi,et al.  Selective Palladium‐Catalyzed Suzuki–Miyaura Reactions of Polyhalogenated Heteroarenes , 2012 .

[37]  Hao Xiong,et al.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Jana Sopkova-de Oliveira Santos,et al.  Structural Characterizations of Oligopyridyl Foldamers, α-Helix Mimetics , 2012, J. Chem. Inf. Model..

[39]  Chengyu Liang,et al.  Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX , 2011, Cell Research.

[40]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[42]  Jana Sopkova-de Oliveira Santos,et al.  Synthesis of New [2,3′:6′,3′′]TerpyridinesUsing Iterative Cross-Coupling Reactions , 2010 .

[43]  Emiko Fire,et al.  The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer , 2010, Nature chemical biology.

[44]  K. Gehring,et al.  Apoptotic Regulation by MCL-1 through Heterodimerization* , 2010, The Journal of Biological Chemistry.

[45]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[46]  A. Batsanov,et al.  Iterative and regioselective cross-couplings of 2-chloro-3,4-diiodopyridine leading to 2,3,4-triheteroarylpyridines , 2010 .

[47]  Erinna F. Lee,et al.  Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands* , 2009, The Journal of Biological Chemistry.

[48]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[49]  L. Poulain,et al.  Bcl‐XL and MCL‐1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis , 2009, International journal of cancer.

[50]  Jana Sopkova-de Oliveira Santos,et al.  Synthesis of dihalo bi- and terpyridines by regioselective Suzuki–Miyaura cross-coupling reactions , 2009 .

[51]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[52]  C. Akgul.  Mcl-1 is a potential therapeutic target in multiple types of cancer , 2009, Cellular and Molecular Life Sciences.

[53]  F. Grespi,et al.  Bcl2 family proteins in carcinogenesis and the treatment of cancer , 2009, Apoptosis.

[54]  Sylvain Rault,et al.  A general synthesis of halo-oligopyridines. The Garlanding concept , 2009 .

[55]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[56]  Erinna F. Lee,et al.  Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. , 2008, Journal of molecular biology.

[57]  S. Gellman,et al.  Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein–protein recognition: Application to the Bim BH3 domain , 2008, Protein science : a publication of the Protein Society.

[58]  C. Tse,et al.  Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models , 2008, Clinical Cancer Research.

[59]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[60]  K. Fylaktakidou,et al.  Recent developments in the chemistry and in the biological applications of amidoximes. , 2008, Current pharmaceutical design.

[61]  Erinna F. Lee,et al.  Structural insights into the degradation of Mcl-1 induced by BH3 domains , 2007, Proceedings of the National Academy of Sciences.

[62]  H. Lincet,et al.  Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. , 2007, Gynecologic oncology.

[63]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[64]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[65]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[66]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[67]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[68]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[69]  Lin Chen,et al.  Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.

[70]  A. Petros,et al.  Structural biology of the Bcl-2 family of proteins. , 2004, Biochimica et biophysica acta.

[71]  S. Rault,et al.  An efficient two-step total synthesis of the quaterpyridine nemertelline. , 2003, The Journal of organic chemistry.

[72]  I. Gojo,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  H. Lincet,et al.  Acquisition of chemoresistance in a human ovarian carcinoma cell line is linked to a defect in cell cycle control , 1998, International journal of cancer.

[74]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[75]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[76]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[77]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[78]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[79]  S. Fesik,et al.  Small molecule Mcl-1 inhibitors for the treatment of cancer. , 2015, Pharmacology & therapeutics.

[80]  Victoria Del Gaizo Moore,et al.  Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? , 2008, Advances in experimental medicine and biology.

[81]  A. Petros,et al.  Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies , 2000, Protein science : a publication of the Protein Society.

[82]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.